iOnctura

Biotech & Life Sciences · Geneva, Switzerland · Founded 2017

Oncology therapies countering immunosuppression in tumors MoreLess

Developer of next-generation bio-molecules intended for the treatment of cancer and fibrosis. The company's bio-molecules include novel therapeutics that modulate key culprits of immunosuppression in the tumor microenvironment, enabling doctors to treat diseases such as cancer faster. Keywords: Healthcare Devices, Services, Supplies, Biomolecule Drugs, Biopharmaceutical Research, Cancer Drug, Cancer Treatment, Fibrotic Diseases Drugs, Oncology Treatment.

Valuation $100–500M

Headcount <100

Total funding $100–500M

Unlock exact values

Company overview

iOnctura company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2017
Headquarters: Geneva, Switzerland
Employees: 34
Open positions: None listed
Dealroom signal: 78.8

Website ↗LinkedIn ↗X ↗

client focusb2bsub industryPharmaceuticalsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorOncologysectorImmune SystemsectorSpinoutsectorEICsectorBiotech and PharmasectorEIC FundsectorWoman FoundersectorHorizon Europe

Valuation & funding

iOnctura funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Jun 2024	$88M	$352M	VI Partners · 3B Future Health Fund · Merck Ventures · Schroders Capital	↗
GRANTOther financing	May 2024	$404K	—	KWF Kankerbestrijding	↗
GRANTOther financing	May 2023	$0	—	Health Holland	↗
GRANTOther financing	Oct 2022	$2.5M	—	European Innovation Council	—
EARLY VCOther financing	Oct 2022	$0	—	EIC Fund	—
DEBTDebt	Sep 2022			FONGIT	↗
SERIES AOther financing	Jul 2020			Inkef · 3B Future Health Fund · VI Partners · Schroder Adveq	—
SERIES AOther financing	Jan 2020			Schroder Adveq · M Ventures · Inkef · VI Partners	↗
SPINOUTOther financing	Jun 2017			EPFL Swiss Federal Polytechnic School of Lausanne	—
CORPORATE SPINOUTOther financing	Jun 2017			Merck KGaA	↗

Showing 10 recorded eventsUnlock the complete deal history →

Growth signals

iOnctura website traffic

Latest recorded traffic for iOnctura is 80 monthly website visits, down 55.6% over the last three months. iOnctura's team grew 9.7% over the past year.

Latest monthly visits80 3-month web change-55.6% 1-year team growth+9.7%

Monthly website visits98 observations · Nov 2016–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

iOnctura compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NPNETRIS PharmaMonoclonal antibodies overcoming cancer therapy resistance.	Lyon, France	Operational	20	$20M	$33M
REResistellOffers an alternative to culture-based antibiogram, the gold standard in antibiotic susceptibility testing (AST)	Muttenz, Switzerland	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
ELEltheraBringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs	Schlieren, Switzerland	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
PEPeptomycFoundational anti-MYC mini-proteins for cancer treatment	Barcelona, Spain	Operational
HEHEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy \| A single platform for defeating cancer and much more	Orsay, France	Operational
ATAmal TherapeuticsDeveloping and progressing therapeutic cancer vaccines	Geneva, Switzerland	Acquired

Showing 8 of the closest matchesCompare every metric →

Talent graph

iOnctura's talent

Book a demo to see the people

Team profiled 13 named & role-tagged

Founders /100 quality score

Key operators 6 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

15 investors on iOnctura's cap table

Sourced from Dealroom's funding and investor records.

Seed 3 investors entered at this stage

European Innovation Council

Health Holland

KWF Kankerbestrijding

Series A 9 investors entered at this stage

M Ventures

Inkef

VI Partners

Schroder Adveq

3B Future Health Fund

EIC Fund

Syncona

Merck Ventures

Schroders Capital

Series B+ 2 investors entered at this stage

Merck KGaA

FONGIT

Other known 1 additional known investor

EPFL Swiss Federal Polytechnic School of Lausanne

Global footprint

Where iOnctura has talent and traffic

Workforce by country

5 countries with
team presence

🇨🇭 Switzerland46.1%

🇬🇧 United Kingdom19.2%

🇳🇱 Netherlands11.5%

🇩🇪 Germany11.5%

🇺🇸 United States11.5%

5 countries shown

In the news

Latest news about iOnctura

Recent press, funding announcements, and product moves mentioning iOnctura — open to read from the original sources.

See all news

Market sentiment

What the market is saying about iOnctura

An AI-synthesized read of the highest-engagement posts about iOnctura on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See iOnctura’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.